Application of iron chelating agent in preparation of medicine for treating or preventing polyomavirus infection

A polyoma virus and iron chelating agent technology, applied in the preparation of medicines for treating or preventing polyoma virus infection or inhibiting polyoma virus, the field of iron chelating agents can solve the problem that no iron chelating agent has been found to treat or prevent polyoma virus-related diseases And other issues

Pending Publication Date: 2022-02-22
SHANGHAI PUBLIC HEALTH CLINICAL CENT
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no reports on the use of iron chelators in the treatment or prevention of polyomavirus-related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of iron chelating agent in preparation of medicine for treating or preventing polyomavirus infection
  • Application of iron chelating agent in preparation of medicine for treating or preventing polyomavirus infection
  • Application of iron chelating agent in preparation of medicine for treating or preventing polyomavirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0189] Embodiment 1: the inhibitory effect research of iron chelating agent to BK virus

[0190] The purpose of this example is to study the inhibitory effect of iron chelators on BK virus (BKV) in cells.

[0191] 1.1 Dissolve deferasirox (DFS), deferoxamine (DFA) and deferiprone (DFP) in DMSO or PBS, respectively, and prepare 250mM, 100mM and 100mM concentration storage solutions for subsequent use .

[0192] 1.2 Use 0.25% Trypsin-0.1% EDTA to digest HRPTEPIC and TCCSUP cells in the logarithmic phase at 3×10 5 The number of cells / well was seeded into 6-well plate, 2ml per well. The above two types of cells were infected within 24 hours of the cell seeding plate, and the cell supernatant in the 6-well plate was aspirated as much as possible, and replaced with the corresponding medium containing 0.5 MOI BKV. After 2 hours of infection, the supernatant was discarded and replaced with a drug-free medium and a medium containing 100 μM deferasirox, 100 μM deferoxamine, and 100 μ...

Embodiment 2

[0198] Embodiment 2: the research of iron chelating agent anti-BK virus effect and iron ion level

[0199] The purpose of this example is to study the inhibitory effect of iron chelators on BK virus in the presence of iron ions.

[0200] 2.1 Dissolve deferasirox, deferoxamine, and deferiprone in DMSO or PBS, respectively, and prepare stock solutions at concentrations of 250 mM, 100 mM, and 100 mM, respectively, for subsequent use.

[0201] 2.2 Use 0.25% Trypsin-0.1% EDTA to digest HRPTEPIC and TCCSUP cells in the logarithmic phase at 3×10 5 The number of cells / well was seeded into 6-well plate, 2ml per well. The above two types of cells were infected within 24 hours of the cell seeding plate, and the cell supernatant in the 6-well plate was aspirated as much as possible, and replaced with the corresponding medium containing 0.5 MOI BKV. After 2 hours of infection, the supernatant was discarded, and replaced with a drug-free medium and a medium containing 10 μM deferasirox, 2...

Embodiment 3

[0207] Embodiment 3: the research of iron chelator treatment or prevention BK virus-associated disease

[0208] The purpose of this example is to study the inhibitory effect of iron chelators on BK virus in BKV recipient cells by administering iron chelators before and after BK virus infection of cells.

[0209] 3.1 Dissolve deferasirox, deferoxamine, and deferiprone in DMSO or PBS, respectively, and prepare stock solutions at concentrations of 250 mM, 100 mM, and 100 mM, respectively, for subsequent use.

[0210] 3.2 Use 0.25% Trypsin-0.1% EDTA to digest TCCSUP cells grown in logarithmic phase at 3×10 5 The number of cells per well was seeded into 6-well plates and divided into 4 groups. The above-mentioned cells were infected within 24 hours of the cell seed plate, and the cell supernatant in the 6-well plate was blotted as much as possible. The above four groups were replaced with BK virus, BK virus and 25 μM deferasirox, BK virus and 25 μM deferasirox, respectively. 25 μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biological medicines, in particular to an application of an iron chelating agent in preparation of a medicine for treating or preventing polyoma virus infection.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the use of an iron chelator in the preparation of medicines for treating or preventing polyomavirus infection or inhibiting polyomavirus. Background technique [0002] Polyomaviruses are small non-enveloped double-stranded DNA viruses that display restricted species and cell type specificity. A variety of polyomaviruses with oncogenic potential and chronic infection have been identified in humans. JC virus, also known as John Cunningham virus (JCV), is a member of the Polyomaviridae family and is responsible for multifocal leukoencephalopathy (PML), a brain disorder caused by a viral infection that can be life-threatening in severe cases of pathogens. BK virus (BKV) is also a human-specific polyomavirus that is associated with BK virus nephropathy. Infection with JC virus and BK virus is mostly gradual and is usually found in persons infected in early childhood. The incidence preva...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/4196A61K31/16A61K31/4412A61K31/444A61K31/4425A61K31/426A61K31/4184A61K31/53A61P31/20
CPCA61K45/06A61K31/4196A61K31/16A61K31/4412A61K31/444A61K31/4425A61K31/426A61K31/4184A61K31/53A61P31/20A61K2300/00A61P31/12A61K31/44Y02A50/30
Inventor 朱同玉巫国谊石业静孙佳佳侯玉敏吴楠楠胡春兰
Owner SHANGHAI PUBLIC HEALTH CLINICAL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap